
Sellas said topline results from its Phase 3 REGAL trial of GPS in acute myeloid leukemia are expected this month, narrowing earlier fourth-quarter guidance, and its CEO called the treatment a potential 'transformative' immunotherapy if successful. Shares surged 17% in after-hours trading Thursday and about 15% in early Friday premarket. The Q3 net loss was $10.1 million; cash stood at $134.7 million.